JP2024095709A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024095709A5 JP2024095709A5 JP2024050685A JP2024050685A JP2024095709A5 JP 2024095709 A5 JP2024095709 A5 JP 2024095709A5 JP 2024050685 A JP2024050685 A JP 2024050685A JP 2024050685 A JP2024050685 A JP 2024050685A JP 2024095709 A5 JP2024095709 A5 JP 2024095709A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- oncolytic hsv
- immune
- oncolytic
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700584 Simplexvirus Species 0.000 claims 22
- 230000000174 oncolytic effect Effects 0.000 claims 20
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 239000003112 inhibitor Substances 0.000 claims 9
- 230000037361 pathway Effects 0.000 claims 8
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 5
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 claims 4
- 101150027249 RL1 gene Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 230000003213 activating effect Effects 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000000139 costimulatory effect Effects 0.000 claims 3
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 3
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 3
- 230000008488 polyadenylation Effects 0.000 claims 3
- 230000001177 retroviral effect Effects 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- 241000713813 Gibbon ape leukemia virus Species 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000007699 co-inhibitory pathway Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000000799 fusogenic effect Effects 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 229940123189 CD40 agonist Drugs 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 108010062802 CD66 antigens Proteins 0.000 claims 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 claims 1
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 101100195053 Human herpesvirus 1 (strain 17) RIR1 gene Proteins 0.000 claims 1
- 102100034980 ICOS ligand Human genes 0.000 claims 1
- 101710093458 ICOS ligand Proteins 0.000 claims 1
- 108700002232 Immediate-Early Genes Proteins 0.000 claims 1
- 102000002698 KIR Receptors Human genes 0.000 claims 1
- 229940125563 LAG3 inhibitor Drugs 0.000 claims 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 1
- 241000713869 Moloney murine leukemia virus Species 0.000 claims 1
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims 1
- 108010042215 OX40 Ligand Proteins 0.000 claims 1
- 102000004473 OX40 Ligand Human genes 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 239000012668 PD-1-inhibitor Substances 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 102100029198 SLAM family member 7 Human genes 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102000006601 Thymidine Kinase Human genes 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101150085955 US11 gene Proteins 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 108700005077 Viral Genes Proteins 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000015788 innate immune response Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 244000309459 oncolytic virus Species 0.000 claims 1
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1700350.0 | 2017-01-09 | ||
| GBGB1700350.0A GB201700350D0 (en) | 2017-01-09 | 2017-01-09 | Altered virus |
| PCT/GB2018/050048 WO2018127713A1 (en) | 2017-01-09 | 2018-01-09 | Altered virus |
| JP2019537074A JP7520511B2 (ja) | 2017-01-09 | 2018-01-09 | 改変ウイルス |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537074A Division JP7520511B2 (ja) | 2017-01-09 | 2018-01-09 | 改変ウイルス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024095709A JP2024095709A (ja) | 2024-07-10 |
| JP2024095709A5 true JP2024095709A5 (enExample) | 2024-10-18 |
Family
ID=58463943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537074A Active JP7520511B2 (ja) | 2017-01-09 | 2018-01-09 | 改変ウイルス |
| JP2024050685A Pending JP2024095709A (ja) | 2017-01-09 | 2024-03-27 | 改変ウイルス |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537074A Active JP7520511B2 (ja) | 2017-01-09 | 2018-01-09 | 改変ウイルス |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12059444B2 (enExample) |
| EP (2) | EP4635984A3 (enExample) |
| JP (2) | JP7520511B2 (enExample) |
| KR (1) | KR20190104055A (enExample) |
| CN (1) | CN110198724B (enExample) |
| AU (1) | AU2018205763B2 (enExample) |
| BR (1) | BR112019013215A2 (enExample) |
| CA (1) | CA3049496A1 (enExample) |
| DK (1) | DK3565568T3 (enExample) |
| ES (1) | ES3038026T3 (enExample) |
| GB (1) | GB201700350D0 (enExample) |
| IL (1) | IL267949B2 (enExample) |
| MX (2) | MX2019008146A (enExample) |
| WO (1) | WO2018127713A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109312309B (zh) | 2016-01-08 | 2024-04-02 | 雷普利穆内有限公司 | 工程化的病毒 |
| SG11201806134SA (en) | 2016-01-27 | 2018-08-30 | Oncorus Inc | Oncolytic viral vectors and uses thereof |
| CA3029426A1 (en) | 2016-06-30 | 2018-01-04 | Oncorus, Inc. | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| BR112019022488A2 (pt) | 2017-04-28 | 2020-06-16 | Merck Sharp & Dohme Corp. | Biomarcadores para terapêutica do câncer |
| US11612625B2 (en) | 2017-07-26 | 2023-03-28 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| UY37829A (es) | 2017-08-03 | 2019-01-31 | Amgen Inc | Muteínas de interleucina 21 y métodos de tratamiento |
| ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
| JP2021508477A (ja) | 2017-12-29 | 2021-03-11 | オンコラス， インコーポレイテッド | 治療用ポリペプチドの腫瘍溶解性ウイルス送達 |
| MA51631A (fr) | 2018-01-12 | 2020-11-18 | Amgen Inc | Anticorps anti-pd1 et méthodes de traitement |
| CN109762068A (zh) * | 2018-08-09 | 2019-05-17 | 源道隆（苏州）医学科技有限公司 | 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用 |
| MX2021007639A (es) | 2018-12-27 | 2021-08-11 | Amgen Inc | Formulaciones de virus liofilizadas. |
| CN113439123A (zh) | 2019-03-05 | 2021-09-24 | 安进公司 | 溶瘤病毒用于治疗癌症的用途 |
| TW202102543A (zh) | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
| WO2020228828A1 (zh) * | 2019-05-15 | 2020-11-19 | 郑州威瑞生物技术有限公司 | 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法 |
| WO2020243334A1 (en) * | 2019-05-29 | 2020-12-03 | Orbis Health Solutions, Llc | Delivery vectors and particles for expressing chimeric receptors and methods of using the same |
| CN110218707B (zh) * | 2019-05-29 | 2021-10-22 | 上海市公共卫生临床中心 | 一种新型溶瘤病毒及其制备方法和应用 |
| CN114269392A (zh) * | 2019-08-16 | 2022-04-01 | 深圳市亦诺微医药科技有限公司 | 用于全身性施用的包含溶瘤性单纯疱疹病毒的药物组合物 |
| CN110982794B (zh) * | 2020-03-05 | 2020-06-16 | 北京唯源立康生物科技有限公司 | 一种修饰的单纯疱疹病毒 |
| CN110982795B (zh) * | 2020-03-05 | 2020-06-16 | 北京唯源立康生物科技有限公司 | 一种单纯疱疹病毒及其用途 |
| CN114075574A (zh) * | 2020-08-19 | 2022-02-22 | 广东东阳光药业有限公司 | 构建体、溶瘤病毒及其应用 |
| WO2024134495A1 (en) * | 2022-12-20 | 2024-06-27 | Janssen Biotech, Inc. | Oncolytic virus and uses thereof |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
| CA1282721C (en) | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
| US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5698531A (en) | 1989-03-31 | 1997-12-16 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5328688A (en) | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
| US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
| US6040169A (en) | 1991-01-31 | 2000-03-21 | Medical Research Council | Herpes simplex virus-1 deletion variants and vaccines thereof |
| AU682463B2 (en) | 1992-03-31 | 1997-10-09 | Arch Development Corporation | Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis) |
| US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| WO1997012623A1 (en) | 1995-10-06 | 1997-04-10 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
| US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
| GB9700411D0 (en) * | 1997-01-10 | 1997-02-26 | Univ London | Eukaryotic gene expression cassette and uses thereof |
| US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| US7300774B1 (en) | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| CA2388807C (en) | 1999-11-12 | 2013-08-06 | Matthew C. Coffey | Viruses for the treatment of cellular proliferative disorders |
| US7223593B2 (en) | 2000-01-21 | 2007-05-29 | Biovex Limited | Herpes virus strains for gene therapy |
| ES2366608T3 (es) | 2001-03-27 | 2011-10-21 | The General Hospital Corporation | Vectores víricos y su uso en métodos terapéuticos. |
| GB0317511D0 (en) * | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| EP1819735A1 (en) | 2004-11-04 | 2007-08-22 | Pfizer Products Inc. | Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer |
| NZ560844A (en) | 2005-03-08 | 2008-08-29 | Pharmacia & Upjohn Co Llc | Anti-MAdCAM antibody compositions |
| CN105483093A (zh) | 2005-06-23 | 2016-04-13 | 休斯顿大学 | Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途 |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物 |
| EP2307033A4 (en) | 2008-05-29 | 2012-06-13 | Gen Hospital Corp | USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS |
| CN102575227A (zh) | 2008-10-08 | 2012-07-11 | 英特瑞克斯顿股份有限公司 | 表达多种免疫调节剂的工程改造细胞及其应用 |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| WO2011063309A1 (en) | 2009-11-20 | 2011-05-26 | Infinity Pharmaceuticals, Inc. | Methods and compositions for treating hedgehog-associated cancers |
| US20130202639A1 (en) | 2010-03-25 | 2013-08-08 | Konstantin G. Kousoulas | Synthetic Herpes Simplex Viruses for Treatment of Cancers |
| WO2011118866A1 (ko) | 2010-03-26 | 2011-09-29 | 연세대학교 산학협력단 | 네트워크를 통한 심사요청 방법 |
| WO2012038606A1 (en) | 2010-09-24 | 2012-03-29 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
| FI20115914L (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| WO2013112942A1 (en) | 2012-01-25 | 2013-08-01 | Dna Trix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| US20150190505A1 (en) * | 2012-07-30 | 2015-07-09 | Alex Wah Hin Yeung | Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator |
| KR20210008155A (ko) | 2012-08-30 | 2021-01-20 | 암젠 인크 | 단순 헤르페스 바이러스 및 면역 체크포인트 억제제를 사용한 흑색종의 치료방법 |
| US9789182B2 (en) | 2012-10-23 | 2017-10-17 | Bristol-Myers Squibb Company | Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer |
| MX2015010791A (es) | 2013-02-22 | 2015-11-26 | Hoffmann La Roche | Metodos para tratar el cancer y prevenir la resistencia a farmacos. |
| WO2014158811A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
| CN106163532B (zh) | 2013-09-03 | 2019-12-31 | 免疫医疗有限公司 | 以减毒的新城疫病毒为特征的组合物和用于治疗瘤形成的使用方法 |
| LT3021859T (lt) * | 2013-10-25 | 2018-06-11 | Psioxus Therapeutics Limited | Onkolitiniai adenovirusai su heterologiniais genais |
| EP3184641B1 (en) * | 2013-10-28 | 2020-07-08 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Oncolytic hsv vector |
| CN106029889A (zh) | 2013-11-22 | 2016-10-12 | 德那翠丝有限公司 | 表达免疫细胞刺激受体激动剂的腺病毒 |
| US10933106B2 (en) | 2014-02-25 | 2021-03-02 | Deutsches Krebsforschungszentrum | RNA viruses for immunovirotherapy |
| MA39818A (fr) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
| AU2015289081B2 (en) | 2014-07-16 | 2020-02-06 | Transgene Sa | Combination of oncolytic virus with immune checkpoint modulators |
| CN120555373A (zh) * | 2014-07-16 | 2025-08-29 | 特兰斯吉恩股份有限公司 | 用于表达免疫检查点调节因子的溶瘤病毒 |
| US20160040186A1 (en) * | 2014-08-07 | 2016-02-11 | Xiaoyun Liu | Dna construct and method for transgene expression |
| GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
| WO2016118865A1 (en) | 2015-01-23 | 2016-07-28 | Dreamwell, Ltd. | Automated mattress manufacturing process and apparatus |
| CN104987421A (zh) * | 2015-05-13 | 2015-10-21 | 北京比洋生物技术有限公司 | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 |
| CN109312309B (zh) * | 2016-01-08 | 2024-04-02 | 雷普利穆内有限公司 | 工程化的病毒 |
| KR102323872B1 (ko) * | 2016-04-22 | 2021-11-08 | 임비라 컴퍼니 리미티드 | 암치료용 종양 용해성 단순 헤르페스 바이러스(oHSV) 절대 벡터 및 그 구조체의 구조 |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| CN112601547A (zh) * | 2018-06-21 | 2021-04-02 | 雷普利穆内有限公司 | 使用溶瘤病毒的治疗 |
-
2017
- 2017-01-09 GB GBGB1700350.0A patent/GB201700350D0/en not_active Ceased
-
2018
- 2018-01-09 IL IL267949A patent/IL267949B2/en unknown
- 2018-01-09 MX MX2019008146A patent/MX2019008146A/es unknown
- 2018-01-09 CA CA3049496A patent/CA3049496A1/en active Pending
- 2018-01-09 US US16/466,612 patent/US12059444B2/en active Active
- 2018-01-09 WO PCT/GB2018/050048 patent/WO2018127713A1/en not_active Ceased
- 2018-01-09 AU AU2018205763A patent/AU2018205763B2/en active Active
- 2018-01-09 EP EP25186357.7A patent/EP4635984A3/en active Pending
- 2018-01-09 EP EP18701924.5A patent/EP3565568B1/en active Active
- 2018-01-09 DK DK18701924.5T patent/DK3565568T3/da active
- 2018-01-09 JP JP2019537074A patent/JP7520511B2/ja active Active
- 2018-01-09 BR BR112019013215-5A patent/BR112019013215A2/pt unknown
- 2018-01-09 CN CN201880006355.8A patent/CN110198724B/zh active Active
- 2018-01-09 KR KR1020197023554A patent/KR20190104055A/ko not_active Ceased
- 2018-01-09 ES ES18701924T patent/ES3038026T3/es active Active
-
2019
- 2019-07-05 MX MX2025002735A patent/MX2025002735A/es unknown
-
2024
- 2024-03-27 JP JP2024050685A patent/JP2024095709A/ja active Pending
- 2024-07-10 US US18/769,170 patent/US20240358781A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024095709A5 (enExample) | ||
| Rui et al. | Cancer immunotherapies: advances and bottlenecks | |
| Ferris | Immunology and immunotherapy of head and neck cancer | |
| US12397053B2 (en) | Engineered virus | |
| JP7250185B2 (ja) | 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス | |
| JP2020503871A5 (enExample) | ||
| Humeau et al. | Trial watch: intratumoral immunotherapy | |
| JP2019500909A5 (enExample) | ||
| JP2019501670A5 (enExample) | ||
| JP2021529741A (ja) | がん治療 | |
| JP2019501671A5 (enExample) | ||
| CN110381997A (zh) | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 | |
| KR20240132482A (ko) | 항암 백시니아 바이러스와 관문 저해제 병용 요법 | |
| TWI851676B (zh) | 溶瘤病毒用於治療癌症之用途 | |
| US20210154278A1 (en) | Immune gene-drugs expressed in tumor cells activate the systemic immune response against cancer | |
| CN112020510A (zh) | 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物 | |
| Wang et al. | Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? | |
| KR20240024048A (ko) | Nk 세포와 her2 표적 항체를 이용한 암 치료 방법 | |
| JP2022526942A (ja) | 癌のネオアジュバント療法における腫瘍溶解性ウイルスの使用 | |
| Xu et al. | Enhanced cellular therapy: revolutionizing adoptive cellular therapy | |
| Tenesaca et al. | Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors | |
| JPWO2019243847A5 (enExample) | ||
| Oli et al. | Tumour immunotherapy and applications of immunological products: A review of literature | |
| US20220305100A1 (en) | Methods of vaccination and use of cd47 blockade | |
| JPWO2020036635A5 (enExample) |